Summary
Background
The incidence, geographical distribution and clinical relevance of different nontuberculous mycobacteria (NTM) in Croatia are well described. There are few data on the risk factors for developing NTM pulmonary disease (NTM-PD) in this setting.
Methods
We conducted a retrospective cohort study on all Croatian residents with NTM isolated from respiratory samples in the period from 2006 to 2015 with follow-up to 2018. The American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines were used to establish NTM-PD diagnosis. Clinical, radiological and treatment data were collected from hospital records.
Results
Risk analysis calculations were made on the 439 isolation episodes that were classified as definitive NTM-PD (n = 137) or no disease (n = 302). Female gender, presence of bronchiectasis, low BMI and long-term systemic corticosteroid treatment were independent risk factors associated with NTM-PD. Hemoptysis and malaise were presenting symptoms independently associated with NTM-PD. Chronic obstructive pulmonary disease (COPD) and low/moderate dose inhaled corticosteroid (ICS) treatment were not associated with NTM-PD. High dose ICS treatment was a significant risk factor for developing NTM-PD (aOR = 4.73, CI 1.69-13.23 p = 0.003).
Conclusion
The NTM-PD patients in Croatia are similar to those in other published cohorts in terms of their characteristics and risk factors. The significant dose-dependent association between ICS use and NTM-PD adds to the body of evidence suggesting that high dose ICS use is associated with NTM-PD.
Similar content being viewed by others
References
Marras TK, Daley CL. Epidemiology of human pulmonary infection with mycobacteria nontuberculous. Clin Chest Med. 2002;23:553–67.
Van Ingen J, Hoefsloot W, Dekhuijzen PN, et al. The changing pattern of clinical Mycobacterium avium isolation in the Netherlands. Int J Tuberc Lung Dis. 2010;14:1176–80.
Andréjak C, Thomsen VØ, Johansen IS, et al. Nontuberculous pulmonary Mycobacteriosis in Denmark. Am J Respir Crit Care Med. 2010;181:514–21.
Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56:2000535.
Iseman M, Chan E. Underlying host risk factors for nontuberculous mycobacterial lung disease. Semin Respir Crit Care Med. 2013;34:110–23.
Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis. 2004;38:1428–39.
Van Ingen J, Boeree M, Janssen M, et al. Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti tumor necrosis factor therapy. Nat Clin Pract Rheumatol. 2007;3:414–9.
Marras TK, Daley CL. A systematic review of the clinical significance of pulmonary Mycobacterium kansasii isolates in HIV infection. J Acquir Immune Defic Syndr. 2004;36:883–9.
Jankovic M, Sabol I, Zmak L, et al. Microbiological criteria in non-tuberculous mycobacteria pulmonary disease: a tool for diagnosis and epidemiology. Int J Tuberc Lung Dis. 2016;20:934–40.
Jankovic M, Samarzija M, Sabol I, et al. Geographical distribution and clinical relevance of non-tuberculous mycobacteria in Croatia. Int J Tuberc Lung Dis. 2013;17:836–41.
Stevanovic R, Capak K, Benjak T, et al. Croatian health statistics yearbook 2019. 2020; 273-305. https://www.hzjz.hr/hrvatski-zdravstveno-statisticki-ljetopis/hrvatski-zdravstveno-statisticki-ljetopis-za-2019/. Accessed 30 May 2021.
Chan ED, Iseman MD. Slender older women appear to be more susceptible to nontuberculous mycobacterial lung disease. Gend Med. 2010;7:5–18.
Chalermskulrat W, Gilbey JG, Donohue JF. Nontuberculous mycobacteria in women, young and old. Clin Chest Med. 2002;23:675–86.
Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med. 2008;178:1066–74.
Tsuyuguchi K, Suzuki K, Matsumoto H, et al. Effect of oestrogen on Mycobacterium avium complex pulmonary infection in mice. Clin Exp Immunol. 2001;123:428–34.
Chen F, Szymanski EP, Olivier KN, et al. Whole-Exome sequencing identifies the 6q12-q16 linkage region and a candidate gene, TTK, for pulmonary nontuberculous mycobacterial disease. Am J Respir Crit Care Med. 2017;196:1599–604.
Miller L, Hunt JS. Sex steroid hormones and macrophage function. Life Sci. 1996;59:1–14.
Gomez F, Ruiz P, Bernal JA, et al. Enhancement of splenic-macrophage fc gamma receptor expression by treatment with estrogens. Clin Diagn Lab Immunol. 2001;8:806–10.
Tasaka S, Hasegawa N, Nishimura T, et al. Elevated serum adiponectin level in patients with Mycobacterium avium-intracellulare complex pulmonary disease. Respiration. 2010;79:383–7.
Weygaerde YV, Cardinaels N, Bomans P, et al. Clinical relevance of pulmonary non-tuberculous mycobacterial isolates in three reference centres in Belgium: a multicentre retrospective analysis. BMC Infect Dis. 2019;19:1061.
Andréjak C, Nielsen R, Thomsen VØ, et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2012;68:256–62.
Brode SK, Campitelli MA, Kwong JC, et al. The risk of mycobacterial infections associated with inhaled corticosteroid use. Eur Respir J. 2017;50:1700037.
Nanninni LJ, Pole P, Milan SK, et al. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013. https://doi.org/10.1002/14651858.CD006826.pub2
Acknowledgements
All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Goran Glodić, Miroslav Samaržija, Ivan Sabol, Ljiljana Bulat Kardum, Vesna Carević Vladić, Dražen Strelec, Ljiljana Žmak, Ivana Kuhtić, Ante Marušić and Mateja Janković Makek. The first draft of the manuscript was written by Goran Glodić and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
G. Glodić, M. Samaržija, I. Sabol, Lj. Bulat Kardum, V. Carević Vladić, F. Džubur, M. Jakopović, I. Kuhtić, A. Marušić, D. Mihelčić, S. Popović Grle, D. Strelec, T. Šklebar, A.M. Šola, L. Žmak, J. van Ingen and M. Janković Makek declare that they have no competing interests.
Ethical standards
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008The study was approved by the ethics committee of the Croatian Institute of Public Health (file number 001-487/1-10). Informed consent was obtained from all patients for being included in the study.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Glodić, G., Samaržija, M., Sabol, I. et al. Risk factors for nontuberculous mycobacterial pulmonary disease (NTM-PD) in Croatia. Wien Klin Wochenschr 133, 1195–1200 (2021). https://doi.org/10.1007/s00508-021-01923-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00508-021-01923-x